The Defense Department is reportedly seeking Valisure's help in ensuring generic drugs, often manufactured overseas and away from FDA influence, given to military service members are safe and effective
The ruling means some California Zantac lawsuits are likely to go to before juries in the coming months, while appeals move forward over a controversial decision in the federal court system to exclude all plaintiffs' expert testimony.
Rep. Rose DeLauro says GlaxoSmithKline profited from hiding Zantac cancer risks and attempted to discredit evidence the heartburn drug contained cancer-causing chemicals.
Court records indicate GlaxoSmithKline knew Zantac's active ingredient could chemically change into a cancer-causing agent as early as 1982, and that the potential risk was there before the drug was even developed
Zantac lawsuit filings have shifted to New York and other state courts, after a federal judge issued a ruling last month that resulted in dismissal of the litigation.
Merck indicates it has identified the cause of nitrosamine contaminants in some batches of Januvia and Janumet, which occurs during the manufacturing and storage process.
The federal dismissal does not directly affect Zantac lawsuits filed in state courts nationwide, where cases are scheduled to go to trial throughout 2023
A federal judge ruled that, unlike in Zantac claims, Valsartan NDMA lawsuits do not require proof the drug turns into NDMA in the body, because high levels of the cancer-causing chemical were already present in the pills.
Manufacturers still face about 50,000 Zantac cancer lawsuits in state courts, and reached a settlement instead of allowing a jury to hear evidence in a California Zantac trial scheduled to begin in Feb 2023
Inspectors say Valisure appeared to be unfamiliar with key portions of the Food, Drug and Cosmetic Act linked to drug supply chain security.
